Ultimaster™ family, one of the best DES to treat your HBR patients

Ultimaster™ family, one of the best drug eluting stent (DES) to treat your high bleeding risk (HBR) patients<sup>1,2,3</sup>

neutrals-100

Making a meaningful impact on society by addressing the needs of over 2.9 million patients worldwide who have already been treated with an Ultimaster™ family stent.⁴

Featured products: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System, Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System

neutrals-100

Do you know that ± 45% of your patients are high bleeding risk?5,6
Do you know how to define your HBR patient?
Do you know that we are MDR certified for patients at high bleeding risk?
Do you know that the Ultimaster™ family is one of the best DES to treat your HBR patients, based on MASTER DAPT study?
Do you know that we continue to generate data with HBR patients?

neutrals-100

1. Do you know that ± 45% of your patients are high bleeding risk?<sup>5,6</sup>

neutrals-100

The above percentages are derived from the ARC-HBR (Academic Research Consortium for HBR), PRECISE-DAPT (Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy), and J-HBR (Japanese HBR) scores. LM: Left Main

neutrals-100

section-id

section1

2. Do you know how to define your HBR patient?

In interventional cardiology, an HBR patient refers to someone who has a significantly increased risk of bleeding complications, particularly when undergoing procedures like percutaneous coronary intervention (PCI).

Did you know that nearly 70% of your HBR patients meet at least one of the following ARC-HBR criteria?⁵

neutrals-100

Identifying HBR patients is essential to tailor therapy, minimize bleeding risks, and choose appropriate stent types that might reduce the need for prolonged antiplatelet therapy.

neutrals-100

section-id

section2

3. Do you know that we are MDR certified for patients at high bleeding risk?

Ultimaster Nagomi™ and Ultimaster™ Tansei™ are MDR certified for patients at high bleeding risk, including those eligible for dual antiplatelet therapy (DAPT) as short as one month.

This indication was granted thanks to our robust clinical data^1,12,13 and the results of the landmark MASTER DAPT¹ study, further reinforcing the safety and performance of our stent systems for this specific patient population.

neutrals-100

section-id

section3

4. Do you know that the Ultimaster™ family is one of the best DES to treat your HBR patients, based on MASTER DAPT study?

MASTER DAPT, the only study nowadays to define optimal duration of DAPT in HBR patients with sufficient power.¹

variation-1

cards-4

light-grey-bg

true

variation-1-card

image

Design Paper

Learn more

https://pubmed.ncbi.nlm.nih.gov/30703644/

button

variation-1-card

image

Total Population

Learn more

https://www.nejm.org/doi/full/10.1056/NEJMoa2108749

button

variation-1-card

image

OAC Patients

Learn more

https://pubmed.ncbi.nlm.nih.gov/34455849/

button

variation-1-card

image

Non-adherence

Learn more

https://pubmed.ncbi.nlm.nih.gov/35981821/

button

variation-1-card

image

Gender

Learn more

https://pubmed.ncbi.nlm.nih.gov/35580836/

button

variation-1-card

image

15-month results

Learn more

https://pubmed.ncbi.nlm.nih.gov/36137672/

button

variation-1-card

image

MI patients

Learn more

https://pubmed.ncbi.nlm.nih.gov/37045500/

button

variation-1-card

image

Complex patients

Learn more

https://pubmed.ncbi.nlm.nih.gov/37991745/

button

variation-1-card

image

Screening Log

Learn more

https://pubmed.ncbi.nlm.nih.gov/38704291/

button

variation-1-card

image

Geography

Learn more

https://pubmed.ncbi.nlm.nih.gov/38309468/

button

variation-1-card

image

Precise HBR

Learn more

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.072009

button

variation-1-card

image

Diabetes

Learn more

https://www.sciencedirect.com/science/article/abs/pii/S1936879824011506

button

variation-1-card

image

Recurrent Events

Learn more

https://www.jacc.org/doi/10.1016/j.jacc.2025.05.010

button

section-id

section4

What is addressed in the latest ESC guidelines?

A pivotal study that contributed to the European society of cardiology (ESC) guidelines, improving treatment options for acute and chronic HBR patients : ^2,3

5. Do you know that we continue to generate data with HBR patients?

One of the priority subgroups of the NAGOMI COMPLEX study is HBR patients, who represent approximately 45% of patients recruited to date.

Curious about the early findings from the Nagomi Complex study?

Click here to access Prof. Mamas Mamas’s presentation at EuroPCR 2025.

^{This is a presentation of Pr. Mamas Mamas presented at @EuroPCR2025, to allow healthcare professionals to watch the slides on demand. This presentation is to be used for training purposes only and in no case intended for the general public. Any claims and views expressed in this presentation reflect solely the speakers own experiences or opinions and do not necessarily reflect the position of Terumo. No part of the presentation may be reproduced, distributed, transmitted in any form or by any means, electronic or manually, without the prior written consent of Pr. Mamas Mamas.}

section-id

section5

References

text

Valgimigli et al. N Engl J Med 2021;385:1643-55. DOI: 10.1056/NEJMoa2108749

text

Byrne et al. Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.

Vrintz et al. EuropeanHeartJournal, Volume 45, Issue 36, 21 September 2024, Pages 3415–3537, https://doi.org/10.1093/eurheartj/ehae177

link

https://doi.org/10.1093/eurheartj/ehae177

Vrintz et al. EuropeanHeartJournal, Volume 45, Issue 36, 21 September 2024, Pages 3415–3537, https://doi.org/10.1093/eurheartj/ehae177

Data on file at Terumo – 2,9 million patient. Number is based on data of Ultimaster family DES sales since April 2014.

text

https://doi.org/10.1093/eurheartj/ehae177

Data on file at Terumo – 2,9 million patient. Number is based on data of Ultimaster family DES sales since April 2014.

text

https://doi.org/10.1093/eurheartj/ehae177

Ueki et al. EuroIntervention. 2020 Aug28;16(5):371-379. doi: 10.4244/EIJ-D-20-00052.

Data on file at Terumo – 2,9 million patient. Number is based on data of Ultimaster family DES sales since April 2014.

text

https://doi.org/10.1093/eurheartj/ehae177

NAGOMI COMPLEXstudy.Resultspresentedat EuroPCR 2024 and EBC 2024.

CaoDet al. Am Heart J Plus. 2022 Nov 9;24:100227. doi: 10.1016/j.ahjo.2022.100227

link

https://www.sciencedirect.com/science/article/pii/S2666602222001446?via%3Dihub

NAGOMI COMPLEXstudy.Resultspresentedat EuroPCR 2024 and EBC 2024.

Nakamura Met al. EuroIntervention. 2021 Feb 19;16(14):1154–1162. doi: 10.4244/EIJ-D-20-00345

link

https://eur03.safelinks.protection.outlook.com/?url=https://doi.org/10.4244/EIJ-D-20-00345&data=05%7c02%7cAnushka.Shrivas%40terumo-europe.com%7cef3c540541f54c4657cf08dd2bf7c344%7c362b8463aa6b41b1ab75eb48120296bb%7c0%7c0%7c638715065315264590%7cUnknown%7cTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7c0%7c%7c%7c&sdata=8smwGRfZTK/M9C6%2BEOJwjrm5RaQYIQV1v8zzI5WSc/A%3D&reserved=0

NAGOMI COMPLEXstudy.Resultspresentedat EuroPCR 2024 and EBC 2024.

Miura K et al. Circ J. 2020 Aug25;84(9):1560-1567. doi: 10.1253/circj.CJ-20-0395. Epub 2020 Jul 16.

text

Miura K et al. Circ J. 2020 Aug25;84(9):1560-1567. doi: 10.1253/circj.CJ-20-0395. Epub 2020 Jul 16.

text

Fujii T et al. Circ J. 2021 Jan 25;85(2):159-165. doi: 10.1253/circj.CJ-20-0806.

Chiariato et al. J Am Coll Cardiol Intv. 2021 Nov, 14 (22) 2447–2457

link

https://eur03.safelinks.protection.outlook.com/?url=https://www.jacc.org/journal/interventions&data=05%7c02%7cAnushka.Shrivas%40terumo-europe.com%7cef3c540541f54c4657cf08dd2bf7c344%7c362b8463aa6b41b1ab75eb48120296bb%7c0%7c0%7c638715065315282118%7cUnknown%7cTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7c0%7c%7c%7c&sdata=B35gnXKp52kUA801b3eHgO3%2B93Sqa7EX5BhFKsQVLZY%3D&reserved=0

Fujii T et al. Circ J. 2021 Jan 25;85(2):159-165. doi: 10.1253/circj.CJ-20-0806.

Miura K et al. Circ J. 2020 Aug25;84(9):1560-1567. doi: 10.1253/circj.CJ-20-0395. Epub 2020 Jul 16.

text

Hioki et al. J Cardiol. 2021 Aug;78(2):107-113. doi: 10.1016/j.jjcc.2021.03.015. (MODEL U-SES)

Miura K et al. Circ J. 2020 Aug25;84(9):1560-1567. doi: 10.1253/circj.CJ-20-0395. Epub 2020 Jul 16.

text

Godino et al. 2019. Int J Cardiol. 2019 Sep 1:290:52-58. doi: 10.1016/j.ijcard.2019.03.030. (ULISSE registry)

section-id

References